Waiver 'pockets' raise outbreak fears; Merck launches mid-stage Staph vaccine trial;

Vaccine Market

In Oregon, public health officials have identified various communities in the state where there's a high number of parents opting out of the vaccines required for children. And the existence of these pockets of unvaccinated children could raise the risk of outbreaks. Report

Vaccine Research

Austria's Intercell says that Merck has begun a second Phase II trial of its experimental vaccine to combat Staphylococcus aureus infections. The vaccine was developed from a protein antigen discovered by Intercell and licensed to Merck four years ago. Release

Maxygen has been awarded a 2-year, $3.4 million grant from the U.S. Department of Defense to develop technology to advance vaccine research and development. Under the grant, Maxygen will continue development of ParallelaVax technology for rapid generation of vaccine candidates and high-throughput testing in animal models. Maxygen release

Vietnam says it will begin vaccinating people with Acambis' Chimerivax on a trial basis to gauge its effectiveness against dengue fever. Report 

The Infectious Disease Research Institute has obtained a $6.3 million grant to fund its work on a new tuberculosis vaccine. Report

Nobel prize-winning Thomas Weller, whose breakthrough tissue-culture work laid the path for the polio vaccine, has died. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.